Pinnbrook Capital Management LP Acquires Shares of 39,141 Novo Nordisk A/S $NVO

Pinnbrook Capital Management LP bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, HoldingsChannel.com reports. The fund bought 39,141 shares of the company’s stock, valued at approximately $1,991,000.

Other hedge funds also recently modified their holdings of the company. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $30,000. WealthCollab LLC boosted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $44.38 on Friday. The firm has a market cap of $198.17 billion, a PE ratio of 10.42, a PEG ratio of 4.02 and a beta of 0.77. The stock’s fifty day moving average price is $40.17 and its two-hundred day moving average price is $46.47. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NVO shares. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Reuters reported that lower-cost Novo Nordisk weight-loss pills are drawing patients away from compounded medications, which could support branded Wegovy demand and improve prescription conversion. Reuters article
• Positive Sentiment: New Phase 3 ESSENCE data on semaglutide at EASL 2026 showed consistent liver safety and efficacy in MASH patients, including underrepresented groups, reinforcing Novo Nordisk’s broader pipeline value. Yahoo Finance article
• Positive Sentiment: Deutsche Bank maintained a Hold rating but said Novo remains cautiously optimistic on its cagrisema obesity study, suggesting a better readout than the prior disappointing trial could help sentiment. Proactive Investors article
• Neutral Sentiment: Several articles highlighted the intense GLP-1 battle with Eli Lilly, including comparisons of Lilly’s next-gen obesity drug and its strong demand momentum, which underscores competition but does not by itself change Novo’s fundamentals. Seeking Alpha article
• Neutral Sentiment: Deutsche Bank’s separate note kept Novo Nordisk at Hold, reflecting a mixed near-term view rather than a clear catalyst for the shares. Globe and Mail article
• Negative Sentiment: Eli Lilly’s encouraging obesity-drug trial data and strong GLP-1 growth commentary are increasing pressure on Novo Nordisk by sharpening investor focus on competitor momentum in the weight-loss market. Yahoo Finance article

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.